Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Convalescent plasma AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
240 results
  • Convalescent plasma for COVID-19. [Journal Article]
    Cleve Clin J Med. 2020 Aug 05 [Online ahead of print]Mucha SR, Quraishy N
  • Convalescent plasma has been used for over a century to treat various infections. Given the lack of currently available effective treatment for COVID-19, it has re-emerged as a potential therapeutic option. A direct antiviral effect of virus-neutralizing antibodies in convalescent plasma is believed to be main mechanism of action, but indirect effects may also contribute to improved viral clearan…
  • Diagnostic and Treatment Strategies for COVID-19. [Review]
    AAPS PharmSciTech. 2020 Aug 03; 21(6):222.Jamshaid H, Zahid F, … Din FU
  • The world is facing lockdown for the first time in decades due to the novel coronavirus COVID-19 (SARS-CoV-2) pandemic. This has led to massive global economic disruption, placed additional strain on local and global public health resources and, above all, threatened human health. We conducted a review of peer-reviewed and unpublished data, written in English, reporting on the current COVID-19 pa…
  • Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. [Preprint]
    bioRxiv. 2020 Jul 22Weisblum Y, Schmidt F, … Bieniasz PD
  • Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombin…
  • [COVID-19 from the Perspective of Haematology and Haemostaseology]. [Journal Article]
    Dtsch Med Wochenschr. 2020 Jul; 145(15):1044-1050.Spiekermann K, Subklewe M, … von Bergwelt-Baildon M
  • Infection with SARS-COV-2 leads to a number of pathologies in the hematopoetic system that have significant impact on clinical symptoms and mortality. There are 3 stages of infection: (1) early upper respiratory tract infection with fever and lymphopenia (2) pulmonary phase and (3) hyperinflammatory phase with the clinical signs of organ failure such as ARDS/shock. Hyperinflammation, which is tri…
  • COVID-19: a wreak havoc across the globe. [Journal Article]
    Arch Physiol Biochem. 2020 Jul 30 [Online ahead of print]Rehman H, Ahmad MI
  • Coronavirus disease (COVID-19) is an infectious airborne viral pneumonia caused by a novel virus belonging to the family coronaviridae. On February 11, 2019, the Internal Committee on Taxonomy of Virus (ICTV) announced the name of the novel virus as "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One of the proteins present on its membrane i.e. the Spike protein is responsible for …
  • Extremely Preterm Infant Born to a Mother With Severe COVID-19 Pneumonia. [Case Reports]
    J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8:2324709620946621.Easterlin MC, De Beritto T, … Ramanathan R
  • Little is known about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pregnant women, fetuses, and neonates, especially when the virus is contracted early in pregnancy. The literature is especially lacking on the effects of SARS-CoV-2 on extremely preterm (<28 weeks gestation) infants who have underdeveloped immune systems. We report the case of an extremely preterm…
  • Perspectives for the immune plasma treatment of COVID-19. [Journal Article]
    Turk J Med Sci. 2020 Jul 28 [Online ahead of print]Sayinalp B, Çinar OE, HaznedaroĞlu İC
  • SARS-CoV-2 infection was declared as a pandemic by World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already passed those of many previous epidemics. A wide variety of treatment options are being considered for COVID-19, but there is still no definitive treatment or vaccine. This review aims to explain the backgroun…
  • Hazards of the cytokine storm and cytokine-targeted therapy in COVID-19 patients: A Review. [Journal Article]
    J Med Internet Res. 2020 Jul 22 [Online ahead of print]Quirch M, Lee J, Rehman S
  • CONCLUSIONS: Severity of the cytokine storm, measured by elevated levels of IL1B, IFNγ, IP10, and MCP1, was associated with COVID-19 disease severity. Many treatment options with different targets have been proposed during the early stages of the COVID-19 pandemic, ranging from targeting the virus itself to managing the systemic inflammation caused by the virus and the excessive cytokine response. Among the different agents to manage cytokine storm in COVID-19 patients, there is developing support for convalescent plasma therapy particularly for critically-ill and mechanically ventilated patients who are resistant to antivirals and supportive care. Treatment options that were proposed in the beginning phases of the pandemic were multi-dimensional, and further research is needed to develop a more established treatment guideline.
  • International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection. [Review]
    Transfus Med Rev. 2020 Jun 27 [Online ahead of print]Murphy M, Estcourt L, … Dzik S
  • The collection and clinical use of COVID-19 convalescent plasma (CCP) as a therapy for COVID-19 infection is under development and early use in many centers worldwide. We conducted an international survey of centers undertaking studies of CCP to provide understanding of the common themes and differences between them. Sixty-four studies in 22 countries were identified from clinical trial registrie…
  • Pharmaco-Immunomodulatory Therapy in COVID-19. [Review]
    Drugs. 2020 Jul 21 [Online ahead of print]Rizk JG, Kalantar-Zadeh K, … Forthal DN
  • The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of COVID-19. Systemic proinflammatory cytokines and …
  • Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist. [Review]
    Crit Care Explor. 2020 Jun; 2(6):e0154.Motley MP, Bennett-Guerrero E, … Spitzer ED
  • CONCLUSIONS: Available assays test for current or previous severe acute respiratory syndrome-coronavirus-2 infection. Nucleic acid assays such as quantitative, or real-time, polymerase chain reaction and loop-mediated isothermal amplification are ideal for acute diagnosis with polymerase chain reaction testing remaining the "gold standard" to diagnose acute infection by severe acute respiratory syndrome-coronavirus-2, specifically the presence of viral RNA. Assays that detect serum antibodies can theoretically diagnose both acute and remote infection but require time for the patient to develop immunity and may detect nonspecific antibodies. Antibody assays that quantitatively measure neutralizing antibodies are needed to test efficacy of convalescent plasma therapy but are more specialized.
  • Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. [Journal Article]
    Transfus Apher Sci. 2020 Jul 03 [Online ahead of print]Karataş A, İnkaya AÇ, … Göker H
  • Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first identified in Wuhan, China; and spread all over the world. Reverse-transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2 usually returns to negative in 20 days post-infection, but prolonged positivity has been reported up to 63 days. A case whose viral shedding lasted 60 days is reported from China. Herein we report a pati…
  • Plasma-derived therapy: can the survivors of COVID-19 help the defenseless? [Review]
    Diagnosis (Berl). 2020 Jul 21 [Online ahead of print]Majbour N, El-Agnaf O
  • Following the unprecedented global Coronavirus Disease 2019 (COVID-19) outbreak, multiple medical countermeasures ramped up to combat the virus and contain the spread of the pandemic. Despite continued uncertainty and a lack of clarity about the COVID-19, researchers have made tremendous strides in the development of prevention and treatment strategies. In this article, we focus on the use of con…
  • Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. [Journal Article]
    J Exp Med. 2020 11 02; 217(11)Schmidt F, Weisblum Y, … Bieniasz PD
  • The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis …
New Search Next